Medtronic Highlights Studies to Be Presented at Heart Rhythm Society 2009 Annual Scientific Sessions

* Reuters is not responsible for the content in this press release.

Mon May 11, 2009 10:03am EDT 

New Data and Clinical Trial Launches Demonstrate Continued Leadership and
Innovation in Cardiac Rhythm Disease Management
MINNEAPOLIS--(Business Wire)--
Medtronic, Inc. (NYSE: MDT) announced today it will present important data on
cardiac care device therapies and report progress across its cardiac rhythm
disease management pipeline at Heart Rhythm 2009, the annual congress of the
Heart Rhythm Society, taking place in Boston, May 13-16, 2009. 

"The breadth and depth of our presence at Heart Rhythm 2009 underscores the
ongoing innovation behind Medtronic`s Cardiac Rhythm Disease Management
portfolio and our continued leadership in meeting unmet medical needs to improve
the lives of patients," said Pat Mackin, president of the Cardiac Rhythm Disease
Management business and senior vice president at Medtronic. "Our scientists and
engineers continue to transform cardiac disease through innovative therapies and
market-leading disease management, diagnostics and monitoring solutions." 

More than 50 sessions on Medtronic cardiac device studies and therapies will be
presented at Heart Rhythm 2009, including new findings on the safety of
pacemakers designed for use with magnetic resonance imaging (MRI) and advances
in the intervention and management of life-threatening heart rhythm disorders.
Following are the key sessions:

 DATE / TIME          SESSION                    
 Thursday, May 14     Satellite Symposium*       
 
6:30 a.m.           MRI and Pacemakers: Myth   
                      Versus Reality             
                      
*This session is not part 
                      of the Heart Rhythm 2009   
                      Official Scientific        
                      Sessions as planned by the 
                      Heart Rhythm Society       
                      Scientific Sessions        
                      Committee.                 
 Thursday, May 14     Late Breaking Clinical     
 10:30 a.m.           Trial: Medtronic EnRhythm  
                      MRI SureScan Pacing System 
                      Worldwide Randomized       
                      Clinical Trial to Evaluate 
                      New Pacemaker System       
                      Designed for Use During    
                      Magnetic Resonance Imaging 
 Thursday, May 14     OMNI Registry: Time to     
 2 p.m.               First Appropriately Treated 
                      VT/VF Episode in Guideline 
                      vs. Non-Guideline Primary  
                      Prevention ICD Patients:   
                      Preliminary Results from   
                      the OMNI study             
 Friday, May 15       Late Breaking Clinical     
 8 a.m.               Trial: Medtronic MVP Pacing 
                      Mode                       
                      Atrial Pacing or           
                      Ventricular Backup Pacing  
                      in Implantable Cardioverter 
                      -Defibrillator Patients:   
                      The Managed Ventricular    
                      Pacing versus VVI-40 Pacing 
                      (MVP) Trial                
 Friday, May 15       Medtronic Discovery Hub:   
 10:30 a.m.           Decreases in Intrathoracic 
                      Impedance are Associated   
                      with Atrial and Ventricular 
                      Tachyarrhythmias: An       
                      Analysis of 43,356 CRT-D   
                      and ICD devices            


Pat Mackin also will participate in a panel discussion with industry leadership
on "The Future of Device-Based Therapy," to be held from 12:15-1:15 p.m.
Thursday, May 14. 

In addition to the various sessions and study data to be presented at Heart
Rhythm 2009, Medtronic will also announce the initiation of two major clinical
trials that will seek to improve patient outcomes in the areas of heart failure
management and reduction of unnecessary shocks from implantable
cardioverter-defibrillators (ICDs). 

Marshall S. Stanton, M.D., vice president of clinical research for the Cardiac
Rhythm Disease Management business at Medtronic, will present "How Cardiac
Rhythm Management (CRM) Networked Databases Assist Safety Surveillance" at a
special session from 8-9:30 a.m. Thursday, May 14. This complements four
separate abstracts that will be presented on aggregated, de-identified data from
the Medtronic Discovery Hub, the world`s largest source of implantable cardiac
device information collected via the Medtronic CareLink Network. The Medtronic
Discovery Hub, which acquires and distributes data from more than 1.5 million
CareLink transmissions in the United States, will make its debut at the
Medtronic booth (no. 1129). 

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global
leader in medical technology - alleviating pain, restoring health, and extending
life for millions of people around the world. 

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic`s Annual Report on Form 10-K for the year ended
April 25, 2008. Actual results may differ materially from anticipated results.



Medtronic, Inc.
Public Relations:
Kyra Schmitt, 763-526-2490
or
Investor Relations:
Jeff Warren, 763-505-2696 

Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.